The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The orally active urotensin receptor antagonist, KR36676, attenuates cellular and cardiac hypertrophy
Authors
Keywords
-
Journal
BRITISH JOURNAL OF PHARMACOLOGY
Volume 172, Issue 10, Pages 2618-2633
Publisher
Wiley
Online
2015-01-19
DOI
10.1111/bph.13082
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Urotensin II Promotes Atherosclerosis in Cholesterol-Fed Rabbits
- (2014) Yafeng Li et al. PLoS One
- The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
- (2013) Stephen P.H. Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors
- (2013) Stephen P.H. Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
- (2013) Adam J. Pawson et al. NUCLEIC ACIDS RESEARCH
- Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice
- (2012) Zhipeng You et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- EGFR trans-activation by urotensin II receptor is mediated by β-arrestin recruitment and confers cardioprotection in pressure overload-induced cardiac hypertrophy
- (2011) Giovanni Esposito et al. BASIC RESEARCH IN CARDIOLOGY
- Potential Clinical Implications of the Urotensin II Receptor Antagonists
- (2011) Philip Tsoukas et al. Frontiers in Pharmacology
- Role of urotensin II in health and disease
- (2010) Bryan Ross et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- Guidelines for reporting experiments involving animals: the ARRIVE guidelines
- (2010) JC McGrath et al. BRITISH JOURNAL OF PHARMACOLOGY
- Animal research: Reporting in vivo experiments: The ARRIVE guidelines
- (2010) Carol Kilkenny et al. BRITISH JOURNAL OF PHARMACOLOGY
- Chronic urotensin II receptor antagonist treatment does not alter hypertrophy or fibrosis in a rat model of pressure-overload hypertrophy
- (2010) Andrew R. Kompa et al. PEPTIDES
- Urotensin II induction of adult cardiomyocytes hypertrophy involves the Akt/GSK-3β signaling pathway
- (2010) D. Gruson et al. PEPTIDES
- Nonpeptide Urotensin-II Receptor Antagonists: A New Ligand Class Based on Piperazino-Phthalimide and Piperazino-Isoindolinone Subunits
- (2009) Edward C. Lawson et al. JOURNAL OF MEDICINAL CHEMISTRY
- Urotensin II Induces Rat Cardiomyocyte Hypertrophy via the Transient Oxidization of Src Homology 2-Containing Tyrosine Phosphatase and Transactivation of Epidermal Growth Factor Receptor
- (2009) J.-C. Liu et al. MOLECULAR PHARMACOLOGY
- A Novel and Orally Active Poly(ADP-Ribose) Polymerase Inhibitor, KR-33889 [2-[Methoxycarbonyl(4-methoxyphenyl) methylsulfanyl]-1H-benzimidazole-4-carboxylic Acid Amide], Attenuates Injury in in Vitro Model of Cell Death and in Vivo Model of Cardiac Ischemia
- (2008) K.-S. Oh et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Urotensin-II Induces Ear Flushing in Rats
- (2007) J-S Qi et al. BRITISH JOURNAL OF PHARMACOLOGY
- Urotensin-II and cardiovascular remodeling
- (2007) Panayiota Papadopoulos et al. PEPTIDES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More